Receptos Announces Appointment of Erle T. Mast as Director
July 22 2013 - 8:00AM
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company
developing therapeutic candidates for the treatment of immune and
metabolic diseases, today announced the appointment of Erle T. Mast
as a director of the Company. Mr. Mast will serve as a Class I
director with a term of office expiring at the first annual meeting
of stockholders following the date of his appointment. Mr.
Mast will also serve as a member of the Company's Audit
Committee. Mr. Mast is a co-founder of Clovis Oncology, Inc.
and has served as its Executive Vice President and Chief Financial
Officer since 2009. Previously, Mr. Mast served in the same role at
Pharmion Corporation, beginning in 2002. From 1997 through 2002,
Mr. Mast worked for Dura Pharmaceuticals, Inc. and its successor,
Elan Corporation. From 2000 to 2002, he served as Chief Financial
Officer for the Global Biopharmaceuticals business unit for Elan.
From 1997 to 2000, Mr. Mast served as Vice President of Finance for
Dura Pharmaceuticals. Prior to that, Mr. Mast was a partner with
Deloitte & Touche, LLP. Mr. Mast also serves on the board of
directors Zogenix, Inc. Mr. Mast received a B.Sc. in business
administration from California State University Bakersfield.
Faheem Hasnain, President and Chief Executive Officer of the
Company, said, "We are pleased to welcome Erle to the Receptos
Board of Directors. He has extensive experience in the
biotechnology industry and financial expertise with life science
companies. We expect that Erle will provide valuable strategic
contributions as a Board member and we look forward to working with
him."
About Receptos
Receptos is a biopharmaceutical company developing therapeutic
candidates for the treatment of immune and metabolic diseases. The
company's lead program, RPC1063, is a sphingosine 1-phosphate 1
receptor (S1P1R) small molecule modulator candidate for immune
indications, including relapsing multiple sclerosis (RMS) and
inflammatory bowel disease (IBD). The company is also developing
RPC4046, an anti-interleukin-13 (IL-13) antibody for an
allergic/immune-mediated orphan disease, eosinophilic esophagitis
(EoE). Receptos has established expertise in high resolution
protein crystal structure determination, biology and drug discovery
for G-protein-coupled receptors (GPCRs).
CONTACT: Media and Investor Contact:
Graham K. Cooper
Chief Financial Officer, Receptos
(858) 652-5708
gcooper@receptos.com
RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart
From Jun 2024 to Jul 2024
RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart
From Jul 2023 to Jul 2024